Page 141 - சிங்கப்பூர் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The vaccine has a 94.1% efficacy rate against COVID-19. Messenger RNA-pioneering biotechnology company Moderna has announced that it has secured an agreement with Singapore’s Ministry of Health to supply the country with Moderna’s vaccine candidate against COVID-19, mRNA-1273. “We continue to advance the clinical development of mRNA-1273 and the recent positive primary efficacy analysis from our Phase 3 COVE study is an encouraging step forward as we work together to address this global health emergency by delivering a vaccine to the people of Singapore and around the world,” said Moderna’s CEO Stéphane Bancel in a statement. Data from the Phase COVE study, which involved 30,000 participants, has shown an efficacy rate against COVID-19 at 94.1% and against severe COVID-19 at 100%. “Efficacy was consistent across age, race and ethnicity, and gender demographics in the 196 observed cases of COVID-19,” Moderna noted.

National institutes of data safety monitoring boardSingapore ministry of healthNational institutesHealth appointed data safety monitoringதேசிய நிறுவனங்கள் ஆஃப் தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகைசிங்கப்பூர் அமைச்சகம் ஆஃப் ஆரோக்கியம்தேசிய நிறுவனங்கள்ஆரோக்கியம் நியமிக்கப்பட்ட தகவல்கள் பாதுகாப்பு கண்காணிப்பு